NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells
Authors:
- 17 May 2024
- journal article
- research article
- Published by AEPress, s.r.o. in Neoplasma
- Vol. 71 (3)
Abstract
NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cellsKeywords
This publication has 40 references indexed in Scilit:
- Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunitiesInternational Journal of Biological Macromolecules, 2024
- NEK2 affects the ferroptosis sensitivity of gastric cancer cells by regulating the expression of HMOX1 through Keap1/Nrf2Molecular and Cellular Biochemistry, 2024
- NEK2 promotes esophageal squamous cell carcinoma cell proliferation, migration and invasion through the Wnt/β-catenin signaling pathwayDiscover Oncology, 2023
- Overcoming the blood brain barrier in glioblastoma: Status and future perspectiveRevue Neurologique, 2023
- NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexesCancer Letters, 2022
- High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13Acta Neuropathologica, 2022
- The NEK family of serine/threonine kinases as a biomarker for cancerClinical and Experimental Medicine, 2022
- TP53 in bone and soft tissue sarcomasPharmacology & Therapeutics, 2019
- Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaInvestigational New Drugs, 2019
- A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomasNeuroImage: Clinical, 2018